Review
Oncology
Pushpamali De Silva, Marco Aiello, Chunyan Gu-Trantien, Edoardo Migliori, Karen Willard-Gallo, Cinzia Solinas
Summary: Immunotherapy approaches targeting immune checkpoint molecules like CTLA-4 have revolutionized treatment of solid tumors and hematological malignancies by enhancing antitumor immune responses. However, the use of anti-CTLA-4 Abs may lead to autoimmune-like adverse events, though this higher incidence is associated with improved clinical benefit.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.
Article
Oncology
Shuhang Wang, Pei Yuan, Beibei Mao, Ning Li, Jianming Ying, Xiuli Tao, Wei Tang, Lei Zhang, Xiao Geng, Fan Zhang, Qi Xue, Lijia Wu, Henghui Zhang, Shugeng Gao, Jie He
Summary: This study assessed the association of PD-L1 expression, genomic factors, and the response to neoadjuvant immunotherapy in lung cancer. The changes in the tumor immune microenvironment during treatment were also investigated.
NPJ PRECISION ONCOLOGY
(2022)
Review
Health Care Sciences & Services
Hadi Shsm, Usama A. Fahmy, Nabil A. Alhakamy, Mohd G. Khairul-Asri, Omar Fahmy
Summary: The use of immune checkpoint inhibitors in neoadjuvant treatment for bladder cancer before radical cystectomy shows promising results, but further studies with extended follow-up are needed to determine the true impact on survival benefits.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, Hossein Safarpour, Vahid Jafarlou, Antonio Giovanni Solimando, Vito Racanelli, Pankaj Kumar Singh, Souzan Najafi, Darya Javadrashid, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
Summary: The study revealed an increasing trend of CTLA-4 in colorectal cancer (CRC) and the inhibitory molecule can be suppressed by the chemotherapy drug capecitabine. Inhibiting CTLA-4 can reactivate immune cells against tumors, potentially enhancing treatment outcomes.
Review
Oncology
M. Rey-Cardenas, F. Guerrero-Ramos, A. Gomez de Liano Lista, A. Carretero-Gonzalez, H. Bote, M. Herrera-Juarez, L. Carril-Ajuria, M. Martin-Soberon, J. M. Sepulveda, E. G. Billalabeitia, D. Castellano, G. de Velasco
Summary: Urothelial bladder cancer is the most common malignancy of the urinary system, and the use of immunotherapy and immune checkpoint inhibitors has transformed treatment strategies, showing improvements in metastatic disease but posing challenges for locally invasive disease.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y. Wang, Daniela Ramos, Jong Min Choi, Taylor Splawn, Monica Espinoza, Michelle Almarez, Leandria Hosey, Eunji Jo, Susan Hilsenbeck, Christopher I. Amos, R. Taylor Ripley, Bryan M. Burt
Summary: This study compared the effects of monotherapy and combination therapy on pathological response and survival in resectable patients. The results showed that combination therapy can alter the immune microenvironment of malignant pleural mesothelioma tumors and improve overall survival.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Allan Relecom, Maysaloun Merhi, Varghese Inchakalody, Shahab Uddin, Darawan Rinchai, Davide Bedognetti, Said Dermime
Summary: Immune checkpoint inhibitors have shown therapeutic benefits in solid cancers and some hematological malignancies, but predicting treatment response remains challenging. Studies on the dynamics of the immune system and tumor under immune checkpoint blockade have revealed mechanisms of action and adaptive resistance to these therapeutic agents.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Review
Oncology
Shuang Huang, Gang Zheng, Kai Yang
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in malignant solid tumors. The results showed that the addition of CTLA-4 inhibitors did not significantly improve overall response rate and survival outcomes. However, there was an increased risk of grade 3-4 adverse events with the combination therapy. More large-scale and multicenter randomized controlled trials are needed to obtain more reliable results.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Review
Chemistry, Medicinal
Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong, Caiyun Zhong
Summary: This article discusses the role of immune checkpoint blockade in cancer treatment and explores the modulation of immune checkpoint proteins by phytochemicals and their combination effects with immune checkpoint inhibitors in various malignancies.
PHYTOTHERAPY RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati-Maleki
Summary: This study aimed to assess the effect of mono, dual, and triple combinations of CTLA-4, PD-L1, and TIM3 blockade on osteosarcoma cell viability, apoptosis, and migration. The results showed that triple blockade had the most significant impact on cell viability, apoptosis rate, and migration inhibition.
Review
Immunology
Zena N. Willsmore, Ben G. T. Coumbe, Silvia Crescioli, Sara Reci, Ayushi Gupta, Robert J. Harris, Alicia Chenoweth, Jitesh Chauhan, Heather J. Bax, Alexa McCraw, Anthony Cheung, Gabriel Osborn, Ricarda M. Hoffmann, Mano Nakamura, Roman Laddach, Jenny L. C. Geh, Alastair MacKenzie-Ross, Ciaran Healy, Sophia Tsoka, James F. Spicer, Debra H. Josephs, Sophie Papa, Katie E. Lacy, Sophia N. Karagiannis
Summary: CTLA-4 and PD-1 are immune checkpoint molecules that are targets of antibody immunotherapies for malignant melanoma. Combination therapy with immune checkpoint inhibitors may have better outcomes compared to monotherapy in certain patient groups, but also presents challenges and increased rates of adverse events.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Liming Liao, Huilin Xu, Yuhan Zhao, Xiaofeng Zheng
Summary: Immunotherapies based on immune checkpoint blockade have improved cancer therapy outcomes in the past decade. However, some patients show poor responsiveness to this therapy, and the underlying mechanism is not well understood. Recent studies have shown that targeting tumor metabolism in combination with immune checkpoint inhibitors provides new approaches to cancer therapy.
FRONTIERS OF MEDICINE
(2023)